Infliximab Alternatives Compared
| Infliximab | Entyvio (vedolizumab) | Stelara (ustekinumab) |
|
|---|
| Infliximab | Entyvio (vedolizumab) | Stelara (ustekinumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ulcerative Colitis, Crohn's Disease, Crohn's Disease - Active, Ankylosing Spondylitis, Inflammatory Bowel Disease, Behcet's Disease, Bullous Pemphigoid, Celiac Disease, Cogan's... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Stelara is an immunosuppressant medication that works by binding to two inflammatory cytokines, IL-12 and IL-23, which have been identified as important contributors to chronic inflammation. Stelara... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease
Popular comparisons
|
|||||||||||||||||||||||
| More about Infliximab | More about Entyvio (vedolizumab) | More about Stelara (ustekinumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Infliximab has an average rating of 6.8 out of 10 from a total of 291 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 24% reported a negative effect. |
Entyvio has an average rating of 6.2 out of 10 from a total of 162 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
Stelara has an average rating of 7.6 out of 10 from a total of 252 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 15% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Infliximab side effects |
View all Entyvio side effects |
View all Stelara side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Infliximab prices |
View all Entyvio prices |
View all Stelara prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Avsola, Inflectra, Ixifi, Remicade, Renflexis, Zymfentra | Other vedolizumab brands include: Entyvio Pen | Other ustekinumab brands include: Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
228 hours |
600 hours |
1291.2 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 566 drugs are known to interact with Infliximab:
|
A total of 163 drugs are known to interact with Entyvio:
|
A total of 535 drugs are known to interact with Stelara:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
May 20, 2014 |
September 25, 2009 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.